YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[US 100 dollar bill folded into an up arrow on wooden table. Illustration of the concept of inflation, profit, earning and investment] Biotech stocks have reached their highest level since the height of the pandemic after Moderna (MRNA [ht…
Quick Read ARKG's concentrated, active bet on pre-revenue biotech gained 32% YTD but lost 13 more percentage points than GNOM over the past five years. ARKG's $1.4 billion in assets versus GNOM's $75 million gives larger investors meaningf…
The biotech industry has held up well this year despite macroeconomic uncertainty, pricing pressures and regulatory challenges. Strong first-quarter earnings, new drug approvals and encouraging clinical trial updates have kept investor sen…
[Bubble] Petrovich9 The top 10 stocks in the U.S. now represent approximately 45% of total market capitalization, a level of concentration that has broken traditional market trend lines and left investors struggling to determine whether th…
[Lilly Biotechnology Center in San Diego, California, USA.] JHVEPhoto Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]) officially joined the elite group of U.S. companies valued at more than $1T on Friday, becoming the tenth American…
What’s the closest thing to investing in a private equity healthcare fund, where a few big winners can make us forget that the rest were even stocks we owned? I’d argue it is a pair of biotech ETFs that spread their risk, but not too much,…
The HHS said center directors deserve to be supported by managers aligned with aggressive goals “to expeditiously advance therapeutics for rare diseases using the gold standard of science.” Continue Reading View Comments
Gene editing holds substantial promise for treating thousands of diseases – creating incredible opportunities for gene editing stocks. It could help treat the 7,000 diseases caused by genetic disorders, most of which occur with gene mutati…
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks. With the technology, we can fix faulty genes, or replace them with healthier genes in an attempt to cure diseases or hel…
Genomics is the future of medicine. With it, companies are racing to shed light on human health and disease. Over the last two decades, related studies have allowed us to create genetic risk scores. For example, millions of people can get…
Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion from $5.3 billion in 2023. With it, we can remove cells from the body, edit them and reintroduce them back i…
Gene editing is revolutionizing medicine. For example, just weeks ago, the U.S. Federal Drug Administration approved a new gene-editing treatment for sickle cell disease and transfusion-dependent beta-thalassemia, a genetic disorder that p…
Some of the top gene-editing stocks have had immense surge potential. Look at CRISPR Therapeutics (NASDAQ:CRSP), for example. After a positive outcome from a U.S. FDA advisory panel, and eventual U.S. FDA approval of CRSP’s sickle cell tre…
Two factors –lower interest rates and the low valuation of many biotech stocks — are likely to result in many biotech companies being acquired in 2024. Lower interest rates will result in many drug maker stocks being acquired because cheap…
Gene editing is revolutionizing how the world approaches medicine. In fact, by “simply” removing cells from the body, editing them, and reintroducing them, we could help treat sickle-cell anemia, cancers, blood disorders, blindness, cystic…
CRISPR could revolutionize the way we treat thousands of diseases. Currently, there are about 7,000 caused by genetic disorders, which occur when a mutation affects your genes, or when you have the wrong amount of genetic material, as note…
Gene editing stocks present themselves as one of the more lucrative investments in the healthcare sector. Gene editing, a revolutionary take on the science of genetic engineering, has the potential to countless lives around the globe. By i…
CRISPR could revolutionize the way we treat thousands of diseases. Many of these diseases occur when mutations affect genes, or when people have the wrong amount of genetic material, the Cleveland Clinic reported. Fortunately, CRISPR, or c…
Investment company Sightline Wealth Advisors, LLC (Current Portfolio) buys iShares 0-5 Year TIPS Bond ETF, ARK Genomic Revolution ETF, Nuveen Select Tax Free Income Portfolio, Global X Genomics & Biotechnology ETF, First Trust Morningstar…
Swansea, IL, based Investment company Archford Capital Strategies, LLC (Current Portfolio) buys iShares Short Treasury Bond ETF, Global X Autonomous & Electric Vehicles ETF, GLOBAL X FDS, Global X The Global X Video Games & Esports ETF, Gl…
Investment company McGuire Investment Group, LLC (Current Portfolio) buys SPDR Bloomberg 1-3 Month T-Bill ETF, WisdomTree Floating Rate Treasury Fund, BTC iShares Floating Rate Bond ETF, SPDR Bloomberg Investment Grade Floating Rate ETF, G…
Jay Jacobs of Global X ETFs discusses three high-growth plays that have seen strong gains in this rally.
Thematic ETFs The New Sectors? At an industry virtual happy hour recently, an intriguing idea came up: Thematic investing is the realm of entrepreneurial thinking, whereas traditional sector investing is a construct of index providers, and…